CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 30 enrolled
Drug / intervention
Baricitinib +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01925144
NCT01925144Phase 1Completed

Evaluation of the Impact of Increased Gastric pH Following Omeprazole Administration on the Absorption of Baricitinib in Healthy Subjects

Eli Lilly and Company·interventional·Posted Aug 19, 2013·Updated Jun 6, 2017

In Brief

A Phase 1 clinical trial evaluating Baricitinib and Omeprazole for Healthy Volunteers. Completed, enrolled 30 participants across 1 site.

Detailed Summary

The main purpose of this study is to find out how the body will react to a study drug called baricitinib when taken with another drug called omeprazole. For each participant, this study will include 2 periods in fixed order. The study will last approximately 25 days, not including screening.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited Kingdom
Collaborators--

Timeline

Phase 1CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedAug 19, 2013
Enrollment StartOct 1, 2013
Primary CompletionNov 1, 2013
TodayJul 2, 2026
Enrollment to primary: 1 monthPosted 12.9 years ago

Interventions

Baricitinibdrug

Administered orally

Omeprazoledrug

Administered orally